Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J MacFadyen

Showing results (91-100 of 163) with videos related to

Pageof 17
Sort By:
The Journal of Clinical Pharmacology and New Drugs|July 1, 1972
Amantadine-HCl in the treatment of Parkinson's disease: a controlled trialD J MacFadyen, T W Picton, L Zeldowicz, et al.
Current Pharmaceutical Design|May 30, 2006
The role of hyperglycaemia and the hypercoagulable state in the pathogenesis of cardiovascular events in diabetes mellitus: implications for hypertension managementHoong Sern Lim, Robert J MacFadyen, George Bakris, et al.
Journal of Cardiovascular Pharmacology|April 1, 1995
Haemodynamic and renal responses to oral losartan potassium during salt depletion or salt repletion in normal human volunteersJ K Doig, R J MacFadyen, C S Sweet, et al.
British Journal of Clinical Pharmacology|March 1, 1993
Haemodynamic and hormonal responses to oral enalapril in salt depleted normotensive manR J MacFadyen, H L Elliott, P A Meredith, et al.
Journal of Thrombosis and Thrombolysis|January 16, 2007
Effects of low osmolar contrast (iomeprol) on haemorheology and platelet activation in patients with coronary artery diseaseRumi J Jaumdally, Chetan Varma, Robert J MacFadyen, et al.
Biomarkers in Medicine|May 19, 2010
Repeated assessment of physical biomeasures or blood biomarkers for the definition of volume status and cardiac loading in LVSDMarie Jennyfer Ng Kam Chuen, Gregory Y H Lip, Robert J MacFadyen
The American Journal of Cardiology|June 24, 1993
Blood pressure response to the first dose of angiotensin-converting enzyme inhibitors in congestive heart failureJ L Reid, R J MacFadyen, I B Squire, et al.
Cardiovascular Drugs and Therapy|November 8, 2006
Oral omega n3-PUFA therapy (Omacor) has no impact on indices of heart rate variability in stable post myocardial infarction patientsAli Hamaad, W Kaeng Lee, Gregory Y H Lip, et al.
Current Cardiology Reports|August 13, 2004
Effects of dietary fat intake in sudden death: reduction of death with omega-3 fatty acidsKaeng W Lee, Ali Hamaad, Robert J MacFadyen, et al.
British Journal of Clinical Pharmacology|September 1, 1991
The response to the first dose of an angiotensin converting enzyme inhibitor in uncomplicated hypertension--a placebo controlled study utilising ambulatory blood pressure recordingR J MacFadyen, A D Bainbridge, K R Lees, et al.
Pageof 17

Showing results (91-100 of 163) with videos related to

Sort By:
Pageof 17
The Journal of Clinical Pharmacology and New Drugs|July 1, 1972
Amantadine-HCl in the treatment of Parkinson's disease: a controlled trialD J MacFadyen, T W Picton, L Zeldowicz, et al.
Current Pharmaceutical Design|May 30, 2006
The role of hyperglycaemia and the hypercoagulable state in the pathogenesis of cardiovascular events in diabetes mellitus: implications for hypertension managementHoong Sern Lim, Robert J MacFadyen, George Bakris, et al.
Journal of Cardiovascular Pharmacology|April 1, 1995
Haemodynamic and renal responses to oral losartan potassium during salt depletion or salt repletion in normal human volunteersJ K Doig, R J MacFadyen, C S Sweet, et al.
British Journal of Clinical Pharmacology|March 1, 1993
Haemodynamic and hormonal responses to oral enalapril in salt depleted normotensive manR J MacFadyen, H L Elliott, P A Meredith, et al.
Journal of Thrombosis and Thrombolysis|January 16, 2007
Effects of low osmolar contrast (iomeprol) on haemorheology and platelet activation in patients with coronary artery diseaseRumi J Jaumdally, Chetan Varma, Robert J MacFadyen, et al.
Biomarkers in Medicine|May 19, 2010
Repeated assessment of physical biomeasures or blood biomarkers for the definition of volume status and cardiac loading in LVSDMarie Jennyfer Ng Kam Chuen, Gregory Y H Lip, Robert J MacFadyen
The American Journal of Cardiology|June 24, 1993
Blood pressure response to the first dose of angiotensin-converting enzyme inhibitors in congestive heart failureJ L Reid, R J MacFadyen, I B Squire, et al.
Cardiovascular Drugs and Therapy|November 8, 2006
Oral omega n3-PUFA therapy (Omacor) has no impact on indices of heart rate variability in stable post myocardial infarction patientsAli Hamaad, W Kaeng Lee, Gregory Y H Lip, et al.
Current Cardiology Reports|August 13, 2004
Effects of dietary fat intake in sudden death: reduction of death with omega-3 fatty acidsKaeng W Lee, Ali Hamaad, Robert J MacFadyen, et al.
British Journal of Clinical Pharmacology|September 1, 1991
The response to the first dose of an angiotensin converting enzyme inhibitor in uncomplicated hypertension--a placebo controlled study utilising ambulatory blood pressure recordingR J MacFadyen, A D Bainbridge, K R Lees, et al.
Pageof 17